Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter(University of Tübingen), Claus Garbe(University of Tübingen), Wolfgang Gehring(Städtisches Klinikum Karlsruhe), Rudolf Herbst(Helios Klinikum Erfurt), Ulrike Keim, Kerstin Schatton(Heinrich Heine University Düsseldorf), Cord Sunderkötter(MSB Medical School Berlin), Peter Martus(University of Tübingen), Carola Berking(Universitätsklinikum Erlangen), Cornelia Mauch(University Hospital Cologne), Norbert H. Brockmeyer(Deutsches Bergbau-Museum Bochum), Thomas Vogt(University Dermatology), D. Verver(Erasmus MC Cancer Institute), Martin Kaatz(SRH Wald-Klinikum Gera), Werner Hohenberger(Universitätsklinikum Erlangen), Percy Lehmann(Helios Universitätsklinikum Wuppertal), Jan‐Christoph Simon(Leipzig University), Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Jens Ulrich
Cited by 254
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Evaluating the public health impact of health promotion interventions: the RE-AIM framework.
|American Journal of Public Health|1999|7.2k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k